3. Administrative Core Dr. Samuel E. Adunyah and Dr. Steven Wolff, in conjuncfion with the other Partnership Co-Principal Invesfigators, will be responsible for the overall conduct of Partnership acfivities as well as the decision-making processes. These include: 1) oversight of the Partnership's objecfives to strengthen and expand competitive cancer research capabilifies 2) create stable, long-term collaborafive relationships between MMC, TSU and the VICC in cancer research, outreach, training and career development 3) promote a stable, long-term partnership based on mutually beneficial research excellence 4) overall planning, coordination and implementafion of internal and external evaluation activities 5) facilitafion of inter-insfitutional initiafives in cancer research 6) budgetary decisions. The MMC component of the Partnership will be administered and managed through well-established infrastructure under the leadership of the Lead Principal Invesfigator, Dr. Samuel E. Adunyah and Co-Principal Investigator, Dr. Steven Wolff. The administrative core is responsible for providing the support necessary to achieve and maintain the highest standards of excellence in cancer research at MMC. Since inception of the cancer partnership MMC has strengthened its cancer research infrastructure. This expansion of cancer research capability in MMC has gained the support of Departmental Chairs and Deans of the Schools of Medicine and Graduate Studies and Research to which some Partnership invesfigators will be reporting. As part if the overall partnership administrative core, our Administrative Core Leadership will play a key role in determining the overall direction for cancer research activities and cancer research training which meet goals and objectives ofthis Partnership. .

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163069-02
Application #
8381600
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
2
Fiscal Year
2012
Total Cost
$362,431
Indirect Cost
$33,816
Name
Meharry Medical College
Department
Type
DUNS #
041438185
City
Nashville
State
TN
Country
United States
Zip Code
37208
Pellom Jr, Samuel T; Dudimah, Duafalia F; Thounaojam, Menaka C et al. (2017) Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. Oncotarget 8:8604-8621
Hull, Pamela; Emerson, Janice S; Quirk, Meghan E et al. (2017) A Smartphone App for Families With Preschool-Aged Children in a Public Nutrition Program: Prototype Development and Beta-Testing. JMIR Mhealth Uhealth 5:e102
Schlundt, David; Briley, Chiquita; Canada, Barbara et al. (2017) Availability of Low-Fat Milk and Produce in Small and Mid-Sized Grocery Stores After 2014 WIC Final Rule Changes, Tennessee. Prev Chronic Dis 14:E70
Uzhachenko, Roman; Boyd, Kelli; Olivares-Villagomez, Danyvid et al. (2017) Mitochondrial protein Fus1/Tusc2 in premature aging and age-related pathologies: critical roles of calcium and energy homeostasis. Aging (Albany NY) 9:627-649
Choi, Hyeongjwa; Ignacio, Rosa Mistica C; Lee, Eun-Sook et al. (2017) Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-?B in Human Serous Ovarian Epithelial Tumors. Immune Netw 17:121-127
Brown, Shyretha; Tehrani, Shahin; Whalen, Margaret M (2017) Dibutyltin-induced alterations of interleukin 1beta secretion from human immune cells. J Appl Toxicol 37:181-191
Pellom Jr, Samuel T; Singhal, Ashutosh; Shanker, Anil (2017) Prospects of combining adoptive cell immunotherapy with bortezomib. Immunotherapy 9:305-308
Amara, Suneetha; Tiriveedhi, Venkataswarup (2017) The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci 18:
Shanker, Anil; Thounaojam, Menaka C; Mishra, Manoj K et al. (2017) Innate-Adaptive Immune Crosstalk 2016. J Immunol Res 2017:3503207
Selove, Rebecca; Foster, Maya; Wujcik, Debra et al. (2017) Psychosocial concerns and needs of cancer survivors treated at a comprehensive cancer center and a community safety net hospital. Support Care Cancer 25:895-904

Showing the most recent 10 out of 148 publications